Trial Profile
Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Aug 2022 Status changed from active, no longer recruiting to completed.
- 05 Oct 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.